hu7B4393 Frozen Validation Report
342 PRS models · 1,636 protein predictions · 145 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Kidney filtration, urate and stone tendency
near-term focus
Kidney, creatinine, urate, gout and kidney-stone signals are among the clearest findings. This is worth treating as context for routine kidney labs, blood pressure and hydration, not as proof of kidney disease.
Full explanation
This category appeared because several kidney and urate-related genetic signals sit at very high levels. The strongest pattern involves kidney disease, creatinine, urine creatinine, gout, serum urate and kidney-stone tendency.
The signal is not a diagnosis and does not say kidney function is currently abnormal. It means the inherited background leans toward kidney and urate-handling traits that can matter more when combined with blood pressure, dehydration, kidney-stone history, gout symptoms, medicines, or family history.
There is also some complexity in the kidney evidence because filtration-related measures do not all translate cleanly into a single simple direction. For that reason, this card should be read as a reason to keep kidney context visible rather than as a single prediction.
This becomes worth discussing or reviewing if there is high blood pressure, foamy or bloody urine, recurrent flank pain, gout-like joint pain, abnormal kidney blood or urine results, kidney stones, or a family history of kidney disease.
What to watch forKeep routine kidney-function, blood-pressure and uric-acid context visible, especially if gout-like pain, flank pain, urinary changes, high blood pressure, kidney stones or family history become relevant.
Show technical evidence
Risk-score evidence
- chronic kidney disease: risk percentile 99.9%, coverage 100%, PGS004128.
- creatinine: risk percentile 99.8%, coverage 100%, PGS001945.
- creatininein urine: risk percentile 86.3%, coverage 100%, PGS001944.
- gout: risk percentile 96%, coverage 100%, PGS004006.
- serum urate: risk percentile 95.2%, coverage 99%, PGS000126.
- calculus of kidney and ureter: risk percentile 80.4%, coverage 78%, PGS001250.
Protein pathway context
- LILRB5: predicted level percentile 82.9%, R2 0.7926; pathway context only.
Gut inflammation and mouth-ulcer tendency
useful to review
Inflammatory bowel, ulcerative colitis, Crohn's disease and mouth-ulcer signals converge with immune pathway evidence. This is an awareness area, especially if gut symptoms or family history ever appear.
Full explanation
The gut-inflammation evidence is convergent. Several genetic signals point toward inflammatory bowel traits, including ulcerative colitis, Crohn's disease, broader inflammatory bowel disease and mouth ulcers.
Protein pathway evidence adds immune and tissue-repair context, and a gut-inflammation variant adds another supporting lane. This does not diagnose bowel disease, and without symptoms it should be read as background rather than as a current medical finding.
The mouth-ulcer signal matters because it can sit near immune and gut-inflammation biology, but mouth ulcers are common and can have many non-genetic causes. The genetic result simply makes the combination of recurrent oral ulcers and gut symptoms more relevant.
This becomes worth discussing or reviewing if there is persistent diarrhea, blood or mucus in stool, unexplained weight change, recurring mouth ulcers, ongoing abdominal pain, iron deficiency, or a family history of inflammatory bowel disease.
What to watch forTreat recurrent gut inflammation symptoms, blood in stool, persistent abdominal pain, recurring mouth ulcers, unexplained weight change or family history as reasons to bring this genetic context into a clinical conversation.
Show technical evidence
Risk-score evidence
- ulcerative colitis: risk percentile 99%, coverage 100%, PGS001855.
- crohn s disease: risk percentile 95.9%, coverage 83%, PGS001331.
- inflammatory bowel disease: risk percentile 89.7%, coverage 100%, PGS004013.
- mouth ulcers: risk percentile 96.7%, coverage 90%, PGS000947.
- duodenitis: risk percentile 82.9%, coverage 100%, PGS001852.
Protein pathway context
- MST1: predicted level percentile 91.1%, R2 0.6781; pathway context only.
- IL1RAP: predicted level percentile 81.8%, R2 0.706; pathway context only.
- LILRB5: predicted level percentile 82.9%, R2 0.7926; pathway context only.
Candidate variants
- Variant rs10800309 GG: snpedia_context.
Atopic skin and airway barrier
useful to review
Eczema and atopic skin-airway evidence is strong, including a confirmation-required skin-barrier variant. Nasal allergy and psoriasis signals are lower, so the pattern is not uniformly allergic.
Full explanation
This category is built around skin-barrier and airway immune evidence. Eczema, dermatitis and atopic disease signals are high, and a skin-barrier variant with clinical and allergy evidence adds important context.
The result does not mean eczema, asthma or a skin-barrier disorder is present. The variant evidence is confirmation-required, and the genetic-score evidence describes tendency, not certainty.
The pattern is also mixed. Some nasal allergy and psoriasis-related signals are lower, so the strongest read is not simply 'more allergy everywhere.' It is more specific to atopic skin-barrier biology with airway overlap.
This becomes worth discussing or reviewing if there are persistent eczema flares, skin cracking, recurrent itchy rashes, wheeze, asthma-like symptoms, chronic cough, recurrent skin infections, or family history of atopic disease.
What to watch forIf eczema-like rashes, skin cracking, wheeze, chronic cough or strong family history are present, use this as context for skin-barrier and airway review.
Show technical evidence
Risk-score evidence
- atopic eczema: risk percentile 95.5%, coverage 99%, PGS003486.
- eczema dermatitis: risk percentile 95.2%, coverage 87%, PGS000944.
- atopic eczema or atopic disease: risk percentile 91.5%, coverage 98%, PGS003459.
- chronic obstructive pulmonary disease: risk percentile 95.3%, coverage 84%, PGS001333.
- hayfever allergic rhinitis: risk percentile 90.6%, coverage 87%, PGS001259.
- vasomotor and allergic rhinitis: risk percentile 6.8%, coverage 89%, PGS001109.
Protein pathway context
- CCL24: predicted level percentile 85.8%, R2 0.7115; pathway context only.
- KLK12: predicted level percentile 98.8%, R2 0.7889; pathway context only.
- KLK1: predicted level percentile 93.3%, R2 0.6165; pathway context only.
- MBL2: predicted level percentile 83.7%, R2 0.6024; pathway context only.
Candidate variants
- FLG rs61816761 GA: confirmation_required.
- PYHIN1 rs1101999 TT: snpedia_context.
Sleep-breathing and airway mechanics
useful to review
Snoring is an extreme signal, with airway and inflammatory context nearby. This is practical mostly if there is loud snoring, witnessed pauses, morning headaches or daytime sleepiness.
Full explanation
The sleep-breathing category appears because snoring sits at a very high genetic level. Airway and inflammatory evidence also appears elsewhere in the report, especially around atopic airway biology.
This does not diagnose sleep apnea or any breathing disorder. It says that sleep-breathing traits may be more relevant to real-world performance, recovery, blood pressure and daytime energy if symptoms are present.
The broader lifestyle context is not uniformly unfavorable. Tobacco-use and some dependence-related signals are lower, which softens the interpretation around airway irritant behavior, but it does not remove the sleep-breathing signal.
This becomes worth discussing or reviewing if there is loud habitual snoring, witnessed breathing pauses, morning headaches, waking unrefreshed, daytime sleepiness, resistant high blood pressure, or major changes in training recovery.
What to watch forUse loud snoring, witnessed pauses, daytime sleepiness, morning headaches or poor recovery as triggers to review sleep-breathing context.
Show technical evidence
Risk-score evidence
- snoring: risk percentile 99.4%, coverage 100%, PGS002006.
- chronic obstructive pulmonary disease: risk percentile 95.3%, coverage 84%, PGS001333.
- sleep duration: risk percentile 8.8%, coverage 100%, PGS001978.
- tobacco use disorder: risk percentile 15.1%, coverage 100%, PGS001830.
- time from waking to first cigarette: risk percentile 9%, coverage 84%, PGS001532.
Protein pathway context
- CCL24: predicted level percentile 85.8%, R2 0.7115; pathway context only.
- KLK1: predicted level percentile 93.3%, R2 0.6165; pathway context only.
Candidate variants
- FLG rs61816761 GA: confirmation_required.
- PYHIN1 rs1101999 TT: snpedia_context.
Metabolic body-composition divergence
useful to review
Body size and glycemic evidence diverge: lower BMI, waist, weight and fat signals contrast with beta-cell, insulin-secretion, waist-to-hip and low basal-metabolic-rate signals.
Full explanation
This is one of the more nuanced areas. Several body-size signals point lower: BMI, waist circumference, weight, arm fat and arm fat mass are all low. That looks favorable for overall body mass tendency.
At the same time, beta-cell and insulin-secretion traits are high, waist-to-hip patterning is high, and basal metabolic rate is low. That combination suggests body composition and fat distribution may matter more than scale weight alone.
The diabetes-related evidence is not one-directional. Some diabetes and insulin-resistance traits look protective, while a beta-cell-function trait is high. The practical read is divergence, not a simple high-risk or low-risk label.
This becomes worth discussing or reviewing if waist size changes despite stable weight, blood sugar or insulin results become abnormal, energy expenditure feels unusually low, body composition changes with training, or there is a strong family history of diabetes or metabolic disease.
What to watch forPrioritize body-composition habits over scale weight alone; review this context if waist pattern, blood sugar, insulin markers or family history become relevant.
Show technical evidence
Risk-score evidence
- insulin secretion rate: risk percentile 95.4%, coverage 96%, PGS000835.
- insulin resistance: risk percentile 9.7%, coverage 98%, PGS000877.
- basal metabolic rate: risk percentile 91.2%, coverage 96%, PGS003903.
- arm fat percentage: risk percentile 2.1%, coverage 97%, PGS003915.
- arm fat mass: risk percentile 3%, coverage 97%, PGS003919.
Protein pathway context
- INSL3: predicted level percentile 90.7%, R2 0.7312; pathway context only.
- FSHB: predicted level percentile 86.8%, R2 0.6068; pathway context only.
- APOBR: predicted level percentile 83.7%, R2 0.67; pathway context only.
Candidate variants
- RMST rs11109072 CC: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
- Variant rs10799701 GG: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
Cardiac structure and vascular load
useful to review
Heart-structure and heart-event signals are elevated, but cholesterol, rhythm and vessel-wall signals include favorable evidence. The cardiovascular picture is mixed, not uniformly high.
Full explanation
The cardiovascular evidence is mixed. Left-ventricular mass, heart-event and heart-failure-related traits sit high, and there is additional vascular timing and heart-rate context.
At the same time, several lipid and rhythm signals look more favorable: high-cholesterol tendency is low, atrial rhythm traits are lower, one protective cholesterol-related trait is high, and carotid wall context is lower.
This means the heart category should not be read as a blanket prediction. It is most useful as a reminder that structure, blood pressure, exertional symptoms and family history can matter even when lipid tendency looks partly favorable.
This becomes worth discussing or reviewing if there is high blood pressure, chest pressure, unusual shortness of breath with exertion, palpitations, fainting, reduced exercise tolerance, abnormal heart testing, or early heart disease in close relatives.
What to watch forKeep blood pressure, exertional symptoms, palpitations and family history in view; do not rely on favorable cholesterol-related genetics alone.
Show technical evidence
Risk-score evidence
- left ventricular mass index: risk percentile 99.6%, coverage 100%, PGS003427.
- nstemi: risk percentile 94.1%, coverage 82%, PGS001048.
- congestive heart failure nonhypertensive: risk percentile 89.4%, coverage 100%, PGS001842.
- position of the pulse wave peak: risk percentile 83.3%, coverage 90%, PGS001520.
- incident atrial fibrillation: risk percentile 4.3%, coverage 100%, PGS002773.
- atrial fibrillation and flutter: risk percentile 12.9%, coverage 100%, PGS001841.
Protein pathway context
- MST1: predicted level percentile 91.1%, R2 0.6781; pathway context only.
- KLK1: predicted level percentile 93.3%, R2 0.6165; pathway context only.
- APOBR: predicted level percentile 83.7%, R2 0.67; pathway context only.
Candidate variants
- LOC105377979 rs1015451 TT: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs11160190 GG: snpedia_context.
Immune-cell and inflammatory balance
background
Immune evidence spans neutrophils, lymphocytes, inflammation, sarcoidosis, multiple sclerosis, lupus and innate immune proteins. It is broad context, not a diagnosis.
Full explanation
This category captures broad immune tone. Neutrophil percentage and inflammatory-marker evidence are high, lymphocyte percentage is low, and several autoimmune or immune-mediated disease traits are elevated.
Protein pathway evidence reinforces immune signaling, innate immune recognition and inflammation-control biology. Some of the same immune evidence also supports the gut and skin-airway cards.
This should not be read as saying an autoimmune disease is present. The evidence is broad and partly overlapping, so it is best treated as immune-system background that becomes meaningful only with real symptoms, family history or lab findings.
This becomes worth discussing or reviewing if there are persistent unexplained inflammatory symptoms, recurrent fevers, joint swelling, new neurological symptoms, unusual rashes, recurrent infections, abnormal blood counts, or strong family history of autoimmune disease.
What to watch forUse persistent inflammatory symptoms, unusual rashes, joint swelling, neurological symptoms, recurrent infections, abnormal blood counts or family history as reasons to surface this immune context.
Show technical evidence
Risk-score evidence
- neutrophil percentage: risk percentile 99.4%, coverage 96%, PGS003943.
- lymphocyte percentage: risk percentile 1.2%, coverage 96%, PGS003941.
- c reactive protein: risk percentile 88.1%, coverage 94%, PGS000314.
- sarcoidosis: risk percentile 93.9%, coverage 100%, PGS001872.
- multiple sclerosis: risk percentile 88.6%, coverage 100%, PGS001831.
- lupus: risk percentile 87.6%, coverage 100%, PGS001870.
Protein pathway context
- BST1: predicted level percentile 0.3%, R2 0.7006; pathway context only.
- MST1: predicted level percentile 91.1%, R2 0.6781; pathway context only.
- MBL2: predicted level percentile 83.7%, R2 0.6024; pathway context only.
- LILRB5: predicted level percentile 82.9%, R2 0.7926; pathway context only.
- IL1RAP: predicted level percentile 81.8%, R2 0.706; pathway context only.
- CCL24: predicted level percentile 85.8%, R2 0.7115; pathway context only.
Candidate variants
- LOC105376219 rs10980800 TT: snpedia_context.
- SQRDL rs1044032 TT: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
- ZHX2 rs10108684 GG: snpedia_context.
Stress sensitivity, attention and brain-context background
background
Emotional sensitivity and attention-related signals are elevated, while several depression, addiction and alcohol-related signals are lower. Brain-region evidence is research context only.
Full explanation
This category is about brain and behavior tendencies, not diagnosis. Neuroticism, sensitivity and attention-related traits are elevated, and there is neurological protein context.
The pattern is not purely unfavorable. Some depression-related, alcohol-use and addiction-related signals are lower, which adds important nuance to the emotional and attention-related evidence.
Brain-region rows were treated only as research context. They can describe biological background, but they should not be translated into a medical condition, ability level or mental-health diagnosis.
This becomes worth discussing or reviewing if stress sensitivity, attention regulation, anxiety-like symptoms, low mood, sleep disruption, work performance, relationships or family history make the pattern practically relevant.
What to watch forTreat this as a background cue for stress, attention and recovery habits; discuss it only if symptoms, function, sleep or family history make it relevant.
Show technical evidence
Risk-score evidence
- neuroticism score: risk percentile 99.8%, coverage 100%, PGS001996.
- sensitivity hurt feelings: risk percentile 87.4%, coverage 91%, PGS001016.
- attention deficit hyperactivity disorder: risk percentile 86.9%, coverage 100%, PGS003753.
- frequency of unenthusiasm disinterest in last 2 weeks: risk percentile 4.6%, coverage 89%, PGS001396.
- alcohol use disorder: risk percentile 0.1%, coverage 100%, PGS002739.
- addiction risk factors: risk percentile 15.4%, coverage 100%, PGS005215.
Protein pathway context
- DBH: predicted level percentile 91.1%, R2 0.6647; pathway context only.
- PDCD6: predicted level percentile 87.3%, R2 0.6598; pathway context only.
Candidate variants
- LRP1B rs10210358 GG: snpedia_context.
- Variant rs10799701 GG: snpedia_context.
Prostate and male hormone signaling
useful to review
PSA, prostate and male hormone signals are divergent: some prostate-cancer context is present, while predicted prostate protein and benign enlargement signals are lower.
Full explanation
This category is relevant because the subject metadata is male and several prostate or male hormone signals appear. PSA-related evidence is elevated, and prostate cancer variant context is present.
The category is also divergent. A predicted prostate protein signal is lower, benign prostate enlargement tendency is lower, and testosterone-related scores are low while reproductive-hormone proteins are high.
This does not diagnose prostate cancer, prostate enlargement, low testosterone or fertility issues. It simply means prostate and hormone context may be more useful when paired with age, family history, symptoms and actual blood testing.
This becomes worth discussing or reviewing if there is a family history of prostate cancer, urinary flow changes, night-time urination, pelvic symptoms, fertility concerns, low-libido or low-energy concerns, or an age-appropriate conversation about PSA testing.
What to watch forUse family history, urinary symptoms, fertility or hormone concerns, and age-appropriate PSA conversations as the practical triggers for this context.
Show technical evidence
Risk-score evidence
- prostate specific antigenlevels: risk percentile 95%, coverage 84%, PGS003378.
- hyperplasia of prostate: risk percentile 19%, coverage 80%, PGS001338.
- testosterone: risk percentile 0.3%, coverage 100%, PGS001914.
- testosterone nmol l: risk percentile 1.1%, coverage 93%, PGS000696.
- sex hormone binding globulin: risk percentile 0.7%, coverage 100%, PGS001977.
Protein pathway context
- KLK3: predicted level percentile 15%, R2 0.6695; pathway context only.
- INSL3: predicted level percentile 90.7%, R2 0.7312; pathway context only.
- FSHB: predicted level percentile 86.8%, R2 0.6068; pathway context only.
Candidate variants
- KLK2 rs10424878 GG: snpedia_context.
- EEFSEC rs10934853 CC: snpedia_context.
- Variant rs10505483 CC: snpedia_context.
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
- LRP1B rs10210358 GG: snpedia_context.
Colorectal and digestive tract background
background
Early colorectal cancer and benign digestive-tract signals appear with colorectal variant context. This is screening-context evidence, not a cancer finding.
Full explanation
This category is separate from the gut-inflammation card. It focuses on digestive-tract and colorectal background evidence, including early colorectal cancer, benign digestive neoplasm and colorectal variant context.
The evidence does not mean cancer or polyps are present. It means standard screening context, family history and symptom history matter more when interpreting the genetic background.
Some digestive signals point to gallbladder or hernia-related traits rather than colorectal disease. That makes this a broader digestive-tract awareness category, not a single disease claim.
This becomes worth discussing or reviewing if there is rectal bleeding, persistent change in bowel habit, unexplained anemia, unexplained weight loss, strong family history of colorectal cancer, or questions about when to begin standard screening.
What to watch forUse family history, rectal bleeding, persistent bowel changes, unexplained anemia or screening-age questions as triggers to bring this context into care planning.
Show technical evidence
Risk-score evidence
- benign neoplasm of other parts of digestive system: risk percentile 96.5%, coverage 100%, PGS001812.
- anal and rectal polyp: risk percentile 5.2%, coverage 100%, PGS001859.
- cholecystitis: risk percentile 97.1%, coverage 88%, PGS000942.
- hiatus hernia: risk percentile 81.1%, coverage 89%, PGS000939.
- diaphragmatic hernia: risk percentile 80%, coverage 90%, PGS001050.
Candidate variants
- Intergenic rs10795668 GG: snpedia_context.
Spine, bone and load tolerance
background
Disc-disorder tendency is elevated, while heel-bone ultrasound and several joint or foot traits look more favorable. Training should emphasize progressive loading and spine-friendly movement.
Full explanation
This category is mixed. Intervertebral disc disorder evidence is elevated, which makes spine tolerance and load management relevant.
At the same time, heel-bone ultrasound traits are elevated in a way that may be favorable for bone-density-related context, and several knee, tendon-cyst and foot-structure signals are lower.
The practical interpretation is not fragility. It is that back and spine load should be built progressively, while using the favorable bone and joint signals as encouragement for consistent resistance training.
This becomes worth discussing or reviewing if there is persistent back pain, pain down the leg, numbness or weakness, recurrent injuries, unusually slow recovery, low-trauma fractures, or a need to change training because of spine symptoms.
What to watch forBuild strength gradually, protect spinal mechanics under fatigue, and review this context if persistent back pain, nerve symptoms, fractures or repeated load-related injuries occur.
Show technical evidence
Risk-score evidence
- other intervertebral disk disorders: risk percentile 94%, coverage 88%, PGS000932.
- heel broadband ultrasound attenuation direct entry: risk percentile 91.2%, coverage 100%, PGS001956.
- heel quantitative ultrasound index direct entry: risk percentile 88.2%, coverage 93%, PGS000952.
- internal derangement of knee: risk percentile 13.7%, coverage 83%, PGS001027.
- ganglion and cyst of synovium tendon and bursa: risk percentile 2%, coverage 100%, PGS001879.
- hallux valgus: risk percentile 4.1%, coverage 100%, PGS001881.
Candidate variants
- PIP4K2B rs1043515 AA: snpedia_context.
Eye and hearing context
background
Cataract and refraction evidence appears alongside more favorable macular and myopia signals. A hearing-related variant needs confirmation before interpretation.
Full explanation
The eye evidence is mixed. Cataract and spherical-power traits are elevated, while myopia diagnosis and macular degeneration traits are lower.
The hearing evidence comes mainly from a confirmation-required variant. That means it should not be treated as proof of hearing loss, but it may be worth knowing if hearing symptoms or family history exist.
Together, this is a sensory-health awareness card rather than a diagnosis. It supports ordinary eye and hearing context more than any immediate conclusion.
This becomes worth discussing or reviewing if there are vision changes, glare or night-driving difficulty, early cataracts in the family, hearing changes, tinnitus, childhood hearing history, or family history of hearing loss.
What to watch forUse vision changes, glare, hearing changes, tinnitus or family history as the practical triggers for eye or hearing review.
Show technical evidence
Risk-score evidence
- cataract: risk percentile 89.9%, coverage 100%, PGS001837.
- spherical power: risk percentile 80.9%, coverage 93%, PGS001100.
- myopia diagnosis: risk percentile 10.5%, coverage 100%, PGS001994.
- macular degenerationof retina nos: risk percentile 11.9%, coverage 100%, PGS001834.
- corneal resistance factor: risk percentile 16.4%, coverage 91%, PGS001383.
- corneal hysteresis: risk percentile 16.7%, coverage 91%, PGS001381.
Candidate variants
- GJB2 rs35887622 AG: confirmation_required.
Blood-cell and iron-related background
background
Reticulocyte, hemoglobin, hematocrit, platelet, monocyte, white-cell and iron-related signals form a mixed blood-cell background. This mainly matters if blood counts or fatigue symptoms are abnormal.
Full explanation
This category is about blood-cell traits rather than a blood disorder diagnosis. Reticulocyte percentage is high, while mean reticulocyte volume, hemoglobin and hematocrit signals are lower.
Immune-cell and platelet-related evidence also appears, and variants add red-cell, white-cell and iron-marker context. These signals overlap with the immune and training-recovery sections.
The pattern is mixed and should not be interpreted without actual blood counts. It is most useful as context if routine blood work, endurance performance or symptoms point in the same direction.
This becomes worth discussing or reviewing if there is unexplained fatigue, pallor, breathlessness with usual activity, abnormal blood counts, recurrent infections, unusual bruising, or a clinician already reviewing iron or blood-cell results.
What to watch forTreat this as context for blood-count or iron discussions only if symptoms, endurance changes or actual blood results make it relevant.
Show technical evidence
Risk-score evidence
- high light scatter reticulocyte percentage: risk percentile 94.2%, coverage 96%, PGS003951.
- mean reticulocyte volume: risk percentile 6.2%, coverage 100%, PGS002003.
- haemoglobin concentration: risk percentile 12.6%, coverage 92%, PGS001400.
- haematocrit percentage: risk percentile 17.2%, coverage 100%, PGS001925.
- mean plateletvolume: risk percentile 13.8%, coverage 96%, PGS003934.
- monocyte count: risk percentile 12.2%, coverage 100%, PGS001968.
Protein pathway context
- APOBR: predicted level percentile 83.7%, R2 0.67; pathway context only.
- MBL2: predicted level percentile 83.7%, R2 0.6024; pathway context only.
- BST1: predicted level percentile 0.3%, R2 0.7006; pathway context only.
Candidate variants
- ATP2B4 rs10900585 TT: snpedia_context.
- LOC105376219 rs10980800 TT: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C9
INTERMEDIATE METABOLIZER
*1/*3
Affected drugs: Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
ABCG2
DECREASED FUNCTION
rs2231142 reference (G)/rs2231142 variant (T)
Affected drugs: See CPIC guidance
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.